Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis

Jung Hyun Park, Dae Sun Kim, Young Joo Cho, Yeon Jung Kim, Soo Young Jeong, Seung Min Lee, Seong Joo Cho, Cheol-Won Yun, Inho Jo, Jae Hwan Nam

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Coxsackievirus B3 (CVB3) is a common agent of viral myocarditis, a major cause of sudden cardiac death, and ultimately dilated cardiomyopathy. However, there is no vaccine in clinical use. In this study, we identified the conserved amino acid sequences in the C-terminal region of the VP2 of the coxsackievirus B group and some echoviruses. The mutant virus, YYFF, with phenylalanines substituted for two tyrosines in these conserved sequences was highly attenuated in vivo and could induce a high neutralizing antibody titer and a cytotoxic T-lymphocyte response against CVB3. Thereby, mutant-virus-immunized mice showed a 100% survival rate and protection against inflammation of the heart and pancreas after lethal dose challenge. Thus, this mutant virus is a good candidate for an attenuated CVB3 vaccine.

Original languageEnglish
Pages (from-to)1974-1983
Number of pages10
JournalVaccine
Volume27
Issue number13
DOIs
Publication statusPublished - 2009 Mar 18

    Fingerprint

Keywords

  • Attenuated vaccine
  • Coxsackievirus
  • VP2

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Park, J. H., Kim, D. S., Cho, Y. J., Kim, Y. J., Jeong, S. Y., Lee, S. M., Cho, S. J., Yun, C-W., Jo, I., & Nam, J. H. (2009). Attenuation of coxsackievirus B3 by VP2 mutation and its application as a vaccine against virus-induced myocarditis and pancreatitis. Vaccine, 27(13), 1974-1983. https://doi.org/10.1016/j.vaccine.2009.01.008